Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is a clinical-stage pharmaceutical company with 5 novel drug candidates, focused on treating Alzheimer's disease (AD). The company has recently changed its FYE and is on track for two major milestones in mid-2026, with over 70% patient enrollment in its Phase 2 CALMA trial and the completion of its AI beta program. Risks include failure to gain regulatory approvals and achieve suitable reimbursement.

Bears say

IGC Pharma is focused on developing cannabinoid-based formulations for treating diseases and conditions, specifically Alzheimer's disease. While the company has reported positive interim results for its investigational drugs, the long road ahead and the limited and transient effects of current Alzheimer's drugs indicate significant risks. Additionally, despite the large potential market for Alzheimer's treatments, the company only has two drugs in later stages of development, making it a high-risk investment.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of May 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.